Carbetocin Versus Syntocinon for Prevention of Postpartum Hemorrhage in Cardiac Patients Undergoing Caesarean Section
Launched by CAIRO UNIVERSITY · Oct 26, 2021
Trial Information
Current as of August 20, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant female single tone \>38 weeks
- • Age :18-45 years old.
- • patient with ASA III
- • Cardiac patients ( mild and moderate mitral stenosis-aortic stenosis valve disease )
- Exclusion Criteria:
- • Other cardiac conditions (valve regurge, cardiomyopathy, heart failure,severe mitral stenosis, severe aortic stenosis, severe pulmonary hypertension)
- • Pregnancy hypertensive disorders (eclampsia,preeclampsia)
- • Abnormal placental attachment (accrete,percreta,increta)
- • Patients with bleeding disorders
- • patient with high risk of postpartum haemorrhage
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials